Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Single-Arm, Open-label, Pivotal Study to Evaluate the Efficacy and Safety of Ersodetug Compared to Baseline in Patients With Inadequately Controlled Hypoglycemia Due to Tumor Hyperinsulinism (Tumor HI)

NCT06881992 is registered in ClinicalTrials.gov with Rezolute as lead sponsor.

NCT NCT06881992
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06881992 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Single-Arm, Open-label, Pivotal Study to Evaluate the Efficacy and Safety of Ersodetug Compared to Baseline in Patients With Inadequately Controlled Hypoglycemia Due to Tumor Hyperinsulinism (Tumor HI)
Lead sponsor
Rezolute
Phase
Phase 3
Overall status
Recruiting
Start date
April 16, 2025
Completion date
September 30, 2027
Enrollment
16 (estimated)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

tumor hyperinsulinism (tumor hi)